Cargando…

New approaches to symptomatic treatments for Alzheimer’s disease

BACKGROUND: Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder. DISCUSSION: There have been no recent approvals of cognitive enhancing agents for AD. The...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cummings, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805095/ https://www.ncbi.nlm.nih.gov/pubmed/33441154 http://dx.doi.org/10.1186/s13024-021-00424-9

Ejemplares similares

Correction to: New approaches to symptomatic treatments for Alzheimer’s disease
por: Cummings, Jeffrey
Publicado: (2021)

Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
por: Buccellato, Francesca R., et al.
Publicado: (2023)

Real-World Use of Symptomatic Treatments in Early Alzheimer’s Disease
por: Garcia, Maria João, et al.
Publicado: (2023)

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
por: Cummings, Jeffrey L., et al.
Publicado: (2019)

Glycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer’s Disease Brain
por: Suttapitugsakul, Suttipong, et al.
Publicado: (2022)

Alzheimer's disease diagnostic criteria: practical applications
por: Cummings, Jeffrey
Publicado: (2012)

Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
por: Pardo-Moreno, Teresa, et al.
Publicado: (2022)

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
por: Morató, Xavier, et al.
Publicado: (2022)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
por: Nadeem, Muhammad Shahid, et al.
Publicado: (2021)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
por: Cummings, Jeffrey
Publicado: (2017)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)
por: DiBello, Julia R., et al.
Publicado: (2023)

Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
por: Cummings, Jeffrey, et al.
Publicado: (2022)

New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
por: Doroszkiewicz, Julia, et al.
Publicado: (2022)

New and emerging treatments for symptomatic tardive dyskinesia
por: Rana, Abdul Qayyum, et al.
Publicado: (2013)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
por: Van Bulck, Michiel, et al.
Publicado: (2019)

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
por: Liss, J. L., et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017)

Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
por: Cummings, Jeffrey L., et al.
Publicado: (2023)

Beyond amyloid: New approaches to Alzheimer's disease treatment
Publicado: (2020)

From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer’s Disease Management
por: Sheikh, Mahtab, et al.
Publicado: (2023)

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Adiponectin as a new paradigm for approaching Alzheimer's disease
por: Song, Juhyun, et al.
Publicado: (2013)

New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease
por: David, Michael, et al.
Publicado: (2022)

Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
por: Zimmer, Jennifer A., et al.
Publicado: (2021)

An electrophysiological perspective on Parkinson’s disease: symptomatic pathogenesis and therapeutic approaches
por: Lee, Lan-Hsin Nancy, et al.
Publicado: (2021)

A practical algorithm for managing Alzheimer's disease: what, when, and why?
por: Cummings, Jeffrey L, et al.
Publicado: (2015)

Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification
por: Lauterbach, Edward C.
Publicado: (2016)

Targetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer’s Disease
por: Yin, Qingqing, et al.
Publicado: (2020)

Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
por: Toniolo, Sofia, et al.
Publicado: (2020)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease
por: Komatović, Katarina, et al.
Publicado: (2022)

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
por: Desantis, Vanessa, et al.
Publicado: (2021)

Therapeutic Cocktail Approach for Treatment of Hyperhomocysteinemia in Alzheimer’s Disease
por: Leon, Michael, et al.
Publicado: (2018)

The costs of developing treatments for Alzheimer's disease: A retrospective exploration
por: Cummings, Jeffrey L., et al.
Publicado: (2021)

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis
por: Dorst, Johannes, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n9o3dgjbeuhsgm4tf9mj6hjjij